Table 2.
Total IgE in serum on different time points from the Phase 1 study.
| Assay | Placebo (n = 22) |
Vaccine (n = 22) |
||||||
|---|---|---|---|---|---|---|---|---|
| Day 1 | Day 21 | Day 27 | Day 42 | Day 1 | Day 21 | Day 27 | Day 42 | |
| GMT (95% CI) | 4·5 (2·6, 7·6) |
11·5 (7·1, 18·6) | 12 (9·2, 15·7) | 12·7 (8·3, 19·6) | 4·7 (2·7, 8·4) | 15·3 (10·4, 22·6) | 8·9 (6·1, 12·7) | 10·5 (6·7, 16·4) |
| Median (IQR) | 3·3 (1·6, 15) | 10·5 (6·8, 38·8) | 9·8 (8, 17·3) | 13·8 (7·3, 30·3) | 3·5 (1·1, 8·8) | 16·6 (8·5, 27·7) | 7·5 (5·1, 20·2) | 13·9 (5·5, 28·4) |
Values shown represent IgE concentrations measured in IU/ml. Presented data are geometric mean with geometric SD. No statistically significant difference was observed between Placebo and Vaccine groups at any time points (two-way RM-ANOVA results: p [Group] = 0.1641; p[Day] = 0.003; p[Group*Day] =0.4220).